Frederick L. Locke, MD

Frederick L. Locke, MD, is a medical oncologist and translational investigator dedicated to discovering and implementing ways to use the immune system against lymphoid malignancies. He is the co-leader of the Immuno-Oncology Program at Moffitt Cancer Center, where he also serves as vice-chair and an associate member in the Department of Blood and Marrow Transplant and Cellular Immunotherapy. Dr Locke oversaw the creation of, and leads, Moffitt’s Immune Cell Therapy (ICE-T) program. This cross-departmental effort provides the specialized clinical care of high-risk immunotherapy and cellular therapy patients, regardless of tumor type. 

Dr Locke is a first or senior author on numerous high-impact publications, including articles in The New England Journal of Medicine, The Lancet Oncology, the Journal of Clinical Oncology, JAMA Oncology, and Blood. His research is focused on the development of strategies to promote T-cell responses against tumor-associated antigens for patients with lymphoma and multiple myeloma. He was the worldwide co-lead principal investigator for the ZUMA-1 trial, the first multicenter trial evaluating CD19 chimeric antigen receptor (CAR)T-cell therapy for adult aggressive lymphomas and is a lead principal investigator for several other ongoing trials testing out CD19 CAR T-cell therapy in lymphoma. The work in Dr Locke’s laboratory seeks to uncover mechanisms of resistance to CAR T-cell therapy and develop new strategies to circumvent these processes.